Illumina Corp (ILMN): רווח נקי למניה (EPS TTM)

Illumina, Inc. specializes in high-tech diagnostics. The 12-month net income per share snapshot demonstrates that the current status is 5.79. The company relies on the sale of unique DNA sequencers and consumables. A portion of production and cloud management has been outsourced to external partners. The business is currently undergoing a deep restructuring following the loss of a major asset, focusing on organic growth.
Illumina Platform - פילוחים אנליטיים ומדדי מפתח (ILMN)

To distinguish a sustainable business from a speculative asset, it is necessary to analyze net income per share, which measures the security holder's actual annual income. Illumina, Inc. (ILMN) maintains monopoly control over the consumables market, and the inelastic demand for sequencing confirms the strength of these fundamentals, as reflected in the annual net income per share trend as a capitalization indicator.